Literature DB >> 28496865

Building Atrial Fibrillation Awareness: Is it Time to get Beyond the Top Line?

Sanjeev Saksena1.   

Abstract

Public awareness of atrial fibrillation and its consequences is increasing. In the current environment, this is driven largely by promotion of individual therapies. This editorial discusses the need for greater depth in the discussion of the disease state, its progression and economic consequences as well as the risk of death and disability. The adverse effects of therapies on cardiovascular outcomes is a major need in public education. New initiatives should address these important new insights and needs.

Entities:  

Year:  2013        PMID: 28496865      PMCID: PMC5153074          DOI: 10.4022/jafib.908

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  18 in total

Review 1.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

2.  Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.

Authors:  Sanjeev Saksena; April Slee; Albert L Waldo; Nick Freemantle; Mathew Reynolds; Yves Rosenberg; Snehal Rathod; Shannon Grant; Elizabeth Thomas; D George Wyse
Journal:  J Am Coll Cardiol       Date:  2011-11-01       Impact factor: 24.094

3.  Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists.

Authors:  S Lévy; M Maarek; P Coumel; L Guize; J Lekieffre; J L Medvedowsky; A Sebaoun
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

4.  A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study.

Authors:  Tatjana S Potpara; Goran R Stankovic; Branko D Beleslin; Marija M Polovina; Jelena M Marinkovic; Miodrag C Ostojic; Gregory Y H Lip
Journal:  Chest       Date:  2011-05-26       Impact factor: 9.410

5.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.

Authors:  E J Benjamin; P A Wolf; R B D'Agostino; H Silbershatz; W B Kannel; D Levy
Journal:  Circulation       Date:  1998-09-08       Impact factor: 29.690

6.  An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality.

Authors:  Etienne Aliot; Günter Breithardt; Josep Brugada; John Camm; Gregory Y H Lip; Panos E Vardas; Markus Wagner
Journal:  Europace       Date:  2010-05       Impact factor: 5.214

Review 7.  Hybrid therapy of atrial fibrillation: algorithms and outcome.

Authors:  Sanjeev Saksena; Nandini Madan
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

8.  Long-term rhythm control of drug-refractory atrial fibrillation with "hybrid therapy" incorporating dual-site right atrial pacing, antiarrhythmic drugs, and right atrial ablation.

Authors:  Nandini Madan; Sanjeev Saksena
Journal:  Am J Cardiol       Date:  2004-03-01       Impact factor: 2.778

9.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

10.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.